Jacobio Pharmaceuticals Group (1167) investor relations material

Executive summary

• Revenue surged 1499.3% year-over-year to RMB730.9 million, driven by major global collaborations with AstraZeneca and licensing/service agreements with Allist for key oncology assets.

• Net profit reached RMB600.6 million for H1 2026, reversing a net loss of RMB59.0 million in H1 2025.

• Significant pipeline progress: glecirasib (KRAS G12C inhibitor) approved and commercialized in China; JAB-23E73 (pan-KRAS inhibitor) advanced in clinical trials and out-licensed to AstraZeneca with a US$100 million upfront payment.

• Strengthened global partnerships, notably with AstraZeneca and Allist, to expand R&D and commercialization.

• Announced senior management changes and continued focus on pipeline innovation and global expansion.

Financial highlights

• Revenue: RMB730.9 million (up from RMB45.7 million year-over-year).

• Gross profit: RMB712.7 million (up from RMB45.7 million year-over-year).

• Net profit: RMB600.6 million (vs. net loss of RMB59.0 million year-over-year).

• R&D expenses: RMB92.2 million (down 1.1% year-over-year); administrative expenses: RMB18.6 million (flat year-over-year).

• Cash and bank balances: RMB1,680.1 million as of June 30, 2026.

Outlook and guidance

• Focus on expanding the KRAS and iADC (immunostimulatory ADC) pipelines, with multiple IND applications planned for late 2026.

• Continued global development and commercialization partnerships, especially with AstraZeneca for JAB-23E73.

• Ongoing clinical trials for key assets in NSCLC, CRC, PDAC, and other solid tumors, with further regulatory submissions and commercialization milestones anticipated.

• No interim dividend declared for H1 2026.